Evonik said third-quarter 2026 adjusted EBITDA rose 40% year on year to €629 million, roughly in line with analyst expectations of €633 million. Revenue rose 13% to €3.83 billion, helped by higher chemical prices linked to the Middle East conflict.
Average selling prices rose 10% and volumes grew 2%, lifting the adjusted EBITDA margin to 16.4% from 13.2% a year earlier. The Advanced Technologies division's adjusted EBITDA jumped 87% to €377 million, while Customized Solutions rose 7% to €231 million.
The company reported a net loss of €53 million for the quarter, narrowed from a €106 million loss a year earlier, after €313 million in restructuring charges. Adjusted net income rose to €330 million.
Evonik said it will cut a further 3,200 jobs between 2027 and 2029, on top of 2,800 reductions planned for 2024–2026. It narrowed its 2026 adjusted EBITDA outlook to the upper half of its €2.0–2.2 billion range.
Free cash flow for the first nine months rose to €601 million from €284 million a year earlier. Net financial debt stood at €3.29 billion at the end of September.
